Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Han Ping Loh, Farouq Bin Mahfut, Serene W Chen, Yuhan Huang, Jianxin Huo, Wei Zhang, Kong Peng Lam, Shengli Xu & Yuansheng Yang. (2023) Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies. mAbs 15:1.
Read now
Read now
Lennart Kühl, Annelie K. Schäfer, Sebastian Kraft, Nadine Aschmoneit, Roland E. Kontermann & Oliver Seifert. (2023) eIg-based bispecific T-cell engagers targeting EGFR: Format matters. mAbs 15:1.
Read now
Read now
Dennis J. Underwood, Jeffrey Bettencourt & Zahra Jawad. (2022) The manufacturing considerations of bispecific antibodies. Expert Opinion on Biological Therapy 22:8, pages 1043-1065.
Read now
Read now
Articles from other publishers (19)
Kodchakorn Mahasongkram, Kantaphon Glab-ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang & Wanpen Chaicumpa. (2023) Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines 11:12, pages 1826.
Crossref
Crossref
Lorenzo Manna, Rosa Rapuano Lembo, Asami Yoshioka, Koji Nakamura, Margherita Passariello & Claudia De Lorenzo. (2023) A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies. Cancers 15:22, pages 5345.
Crossref
Crossref
Yan He, Haili Ma, Cong Wang, Zhilong Ai, Qiao Wu, Hongyan Chen & Daru Lu. (2023) A novel brick for bispecific antibody construction. Proteins: Structure, Function, and Bioinformatics 91:8, pages 1065-1076.
Crossref
Crossref
Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie & Aaron R. Hansen. (2023) Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 21:3, pages 366-375.
Crossref
Crossref
Aaron C. Logan. (2023) Lower leukemia burden maximizes the impact of blinatumomab therapy. Cancer 129:9, pages 1316-1318.
Crossref
Crossref
Manoj Kumar Yadav, Ankita Sahu, Anu, Nehaa Kasturria, Anjali Priyadarshini, Archana Gupta, Kanika Gupta & Anil Kumar Tomar. 2023. Protein-based Therapeutics. Protein-based Therapeutics
23
47
.
Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander & Thomas Pabst. (2022) Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers 15:1, pages 44.
Crossref
Crossref
Stefania C. Carrara, Julia Harwardt, Julius Grzeschik, Björn Hock & Harald Kolmar. (2022) TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome. Frontiers in Immunology 13.
Crossref
Crossref
Patrick A. Baeuerle & Holger Wesche. (2022) T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Current Opinion in Oncology 34:5, pages 552-558.
Crossref
Crossref
Ha Gyeong Shin, Ha Rim Yang, Aerin Yoon & Sukmook Lee. (2022) Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. International Journal of Molecular Sciences 23:10, pages 5686.
Crossref
Crossref
Gunnar Houen. 2022. Therapeutic Antibodies. Therapeutic Antibodies
1
25
.
Stephen K. Burley & Helen M. Berman. (2021) Open-access data: A cornerstone for artificial intelligence approaches to protein structure prediction. Structure 29:6, pages 515-520.
Crossref
Crossref
Seung Hyun Kang & Chang-Han Lee. (2021) Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy. Biotechnology and Bioprocess Engineering 26:3, pages 295-311.
Crossref
Crossref
Matthew Collins, Sahar Awwad, Nkiru Ibeanu, Peng T. Khaw, David Guiliano, Steve Brocchini & Hanieh Khalili. (2021) Dual-acting therapeutic proteins for intraocular use. Drug Discovery Today 26:1, pages 44-55.
Crossref
Crossref
Marion Subklewe. 2021. Acute Myeloid Leukemia. Acute Myeloid Leukemia
339
347
.
Melvyn LittleMelvyn Little. 2021. Antibodies for Treating Cancer. Antibodies for Treating Cancer
109
125
.
John D. Westbrook, Rose Soskind, Brian P. Hudson & Stephen K. Burley. (2020) Impact of the Protein Data Bank on antineoplastic approvals. Drug Discovery Today 25:5, pages 837-850.
Crossref
Crossref
Shili Sun, Huixi Zou, Lin Li, Qi Liu, Ning Ding, Lili Zeng, Hui Li & Shengjun Mao. (2019) CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape. International Journal of Pharmaceutics 568, pages 118518.
Crossref
Crossref
Peter Valent, Irina Sadovnik, Gregor Eisenwort, Karin Bauer, Harald Herrmann, Karoline V. Gleixner, Axel Schulenburg, Werner Rabitsch, Wolfgang R. Sperr & Dominik Wolf. (2019) Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. International Journal of Molecular Sciences 20:17, pages 4233.
Crossref
Crossref